ĐỒNG THUẬN CHUYÊN GIA VỀ VAI TRÒ CỦA THUỐC ĐỐI QUANG TỪ ĐẶC HIỆU TẾ BÀO GAN TRONG CHẨN ĐOÁN UNG THƯ BIỂU MÔ TẾ BÀO GAN
Nội dung chính của bài viết
Tóm tắt
Một số đồng thuận của các chuyên gia Hàn quốc và Việt Nam về giá trị của cộng hưởng từ gan mật với thuốc đối quang từ đặc hiệu mô gan trong chẩn đoán, tầm soát ung thư biểu mô tế bào gan cũng như đưa ra các kết luận và khuyến cáo về vấn đề này.
Từ khóa
Ung thư biểu mô tế bào gan, cộng hưởng từ. thuốc đối quang từ đặc hiệu mô gan
Chi tiết bài viết
Tài liệu tham khảo
1. Murakami T, Sofue K, Hori M. Diagnosis of Hepatocellular Carcinoma Using Gd-EOB-DTPA MR Imaging. Magn Reson Med Sci. 2021;21(1):168-181. doi:10.2463/mrms.rev.2021-0031
2. Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology. 2014;272(3):635-654. doi:10.1148/radiol.14132361
3. Kudo M, Kawamura Y, Hasegawa K, et al. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer. 2021;10(3):181-223. doi:10.1159/000514174
4. Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol. 2022;28(4):583-705. doi:10.3350/cmh.2022.0294
5. Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317-370. doi:10.1007/s12072-017-9799-9
6. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182-236. doi:10.1016/j.jhep.2018.03.019
7. Bộ Y Tế. Hướng dẫn chẩn đoán và điều trị ung thư biểu mô tế bào gan. Published online 2020.
8. Park HJ, Lee TY, Kim SY, et al. Hypervascular transformation of hepatobiliary phase hypointense nodules without arterial phase hyperenhancement on gadoxetic acid-enhanced MRI: long-term follow-up in a surveillance cohort. Eur Radiol. 2022;32(8):5064-5074. doi:10.1007/s00330-022-08623-8
9. Hanna RF, Miloushev VZ, Tang A, et al. Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdom Radiol N Y. 2016;41(1):71-90. doi:10.1007/s00261-015-0592-8
10. Kim HD, Lim YS, Han S, et al. Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival. Gastroenterology. 2015;148(7):1371- 1382. doi:10.1053/j.gastro.2015.02.051
11. Jiang H, Wei J, Fu F, et al. Predicting microvascular invasion in hepatocellular carcinoma: A dual-institution study on gadoxetate disodium-enhanced MRI. Liver Int. 2022;42(5):1158-1172. doi:10.1111/liv.15231
12. Ueno A, Masugi Y, Yamazaki K, et al. OATP1B3 expression is strongly associated with Wnt/β-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma. J Hepatol. 2014;61(5):1080-1087. doi:10.1016/j.jhep.2014.06.008
13. Kitao A, Matsui O, Yoneda N, et al. Hepatocellular Carcinoma with β-Catenin Mutation: Imaging and Pathologic Characteristics. Radiology. 2015;275(3):708-717. doi:10.1148/radiol.14141315
14. Kudo M. Gd-EOB-DTPA-MRI Could Predict WNT/β-Catenin Mutation and Resistance to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma. Liver Cancer. 2020;9(5):479-490. doi:10.1159/000509554
2. Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology. 2014;272(3):635-654. doi:10.1148/radiol.14132361
3. Kudo M, Kawamura Y, Hasegawa K, et al. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer. 2021;10(3):181-223. doi:10.1159/000514174
4. Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol. 2022;28(4):583-705. doi:10.3350/cmh.2022.0294
5. Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317-370. doi:10.1007/s12072-017-9799-9
6. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182-236. doi:10.1016/j.jhep.2018.03.019
7. Bộ Y Tế. Hướng dẫn chẩn đoán và điều trị ung thư biểu mô tế bào gan. Published online 2020.
8. Park HJ, Lee TY, Kim SY, et al. Hypervascular transformation of hepatobiliary phase hypointense nodules without arterial phase hyperenhancement on gadoxetic acid-enhanced MRI: long-term follow-up in a surveillance cohort. Eur Radiol. 2022;32(8):5064-5074. doi:10.1007/s00330-022-08623-8
9. Hanna RF, Miloushev VZ, Tang A, et al. Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdom Radiol N Y. 2016;41(1):71-90. doi:10.1007/s00261-015-0592-8
10. Kim HD, Lim YS, Han S, et al. Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival. Gastroenterology. 2015;148(7):1371- 1382. doi:10.1053/j.gastro.2015.02.051
11. Jiang H, Wei J, Fu F, et al. Predicting microvascular invasion in hepatocellular carcinoma: A dual-institution study on gadoxetate disodium-enhanced MRI. Liver Int. 2022;42(5):1158-1172. doi:10.1111/liv.15231
12. Ueno A, Masugi Y, Yamazaki K, et al. OATP1B3 expression is strongly associated with Wnt/β-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma. J Hepatol. 2014;61(5):1080-1087. doi:10.1016/j.jhep.2014.06.008
13. Kitao A, Matsui O, Yoneda N, et al. Hepatocellular Carcinoma with β-Catenin Mutation: Imaging and Pathologic Characteristics. Radiology. 2015;275(3):708-717. doi:10.1148/radiol.14141315
14. Kudo M. Gd-EOB-DTPA-MRI Could Predict WNT/β-Catenin Mutation and Resistance to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma. Liver Cancer. 2020;9(5):479-490. doi:10.1159/000509554